Gupta Karishma, Mehrotra Vidushri, Fu Pingfu, Scarberry Kyle, MacLennan Gregory T, Gupta Sanjay
Urology Institute, University Hospitals Cleveland Medical Center Cleveland, Ohio 44106, USA.
Department of Urology, Case Western Reserve University School of Medicine Cleveland, Ohio 44106, USA.
Am J Clin Exp Urol. 2022 Aug 15;10(4):266-270. eCollection 2022.
The aim of this study was to determine the biochemical recurrence among Black and White American men with grade group 2-5 prostate cancer managed primarily by radical prostatectomy (RP).
This was a single-institution, retrospective study evaluating biochemical recurrence by self-identified race. 163 patients who underwent RP at the University Hospitals Cleveland Medical Center between 2015-2021 were analyzed for racial differences in age at diagnosis, clinical stage, and preoperative serum prostate-specific antigen (PSA). Patients were followed for PSA recurrence (PSA ≥ 0.2 ng/ml). Multivariate analysis was used to determine clinical and pathologic variables that were significant in predicting biochemical recurrence after RP and to determine whether race was an independent predictor of biochemical recurrence-free survival (BCRFS).
Of 163 patients, 82 (50.3%) were Black Americans and 81 (49.7%) were White Americans with a median age of 62.7 ranging between 38.7 to 76.3 years. The grade-specific distribution of cancer 3+4 was 54.9% 65.4%; 4+3 was 25.6% 30.9%; 4+4 was 7.3% 2.5%; 4+5 was 12.2% 1.2% in Black American and White American men. Univariate analysis of BCRFS using Kaplan-Meier method demonstrated a significant difference among levels of Gleason score between Black Americans and White Americans (P = 0.041). Multivariable analysis after controlling the effects of age, Gleason score exhibited no significant difference of BCRFS comparing Black and White American men (P = 0.145). Specifically, the hazard of biochemical recurrence among Black Americans was 1.6 times (95% CI: 0.85-3.02) compared to White Americans (P = 0.145).
Our study demonstrated a significant difference in BCRFS between Black and White American patients. Additional studies with larger sample size underlying this clinical disparity are warranted.
本研究的目的是确定主要接受根治性前列腺切除术(RP)治疗的2-5级前列腺癌美国黑人和白人男性的生化复发情况。
这是一项单机构回顾性研究,通过自我认定的种族评估生化复发情况。分析了2015年至2021年期间在克利夫兰大学医院医疗中心接受RP的163例患者在诊断年龄、临床分期和术前血清前列腺特异性抗原(PSA)方面的种族差异。对患者进行PSA复发随访(PSA≥0.2 ng/ml)。多变量分析用于确定在预测RP后生化复发方面具有显著意义的临床和病理变量,并确定种族是否是无生化复发生存期(BCRFS)的独立预测因素。
163例患者中,82例(50.3%)为美国黑人,81例(49.7%)为美国白人,中位年龄为62.7岁,范围在38.7至76.3岁之间。美国黑人和白人男性中癌症3+4的分级分布分别为54.9%和65.4%;4+3分别为25.6%和30.9%;4+4分别为7.3%和2.5%;4+5分别为12.2%和1.2%。使用Kaplan-Meier方法对BCRFS进行单变量分析显示,美国黑人和白人之间的Gleason评分水平存在显著差异(P = 0.041)。在控制年龄、Gleason评分的影响后进行多变量分析,结果显示美国黑人和白人男性的BCRFS无显著差异(P = 0.145)。具体而言,与美国白人相比,美国黑人生化复发的风险是其1.6倍(95%CI:0.85-3.02)(P = 0.145)。
我们的研究表明美国黑人和白人患者在BCRFS方面存在显著差异。有必要开展更多基于这一临床差异的大样本研究。